United States

Tongfang Kontafarma Holdings Ltd (1312.HK)

1312.HK on Hong Kong Stock

1:07am EST
Change (% chg)

HK$-0.02 (-3.51%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Tongfang Kontafarma Holdings says HY revenue HK$611.4 million
Wednesday, 30 Aug 2017 10:04am EDT 

Aug 30 (Reuters) - Tongfang Kontafarma Holdings Ltd <1312.HK>::HY revenue hk$611.4 million versus hk$238.8 million.HY loss attributable hk$8.4 million versus loss of hk$18.0 million.  Full Article

Tongfang Kontafarma says unit and Binex enters agreement for establishment of joint venture co
Wednesday, 31 May 2017 10:27am EDT 

May 31 (Reuters) - Tongfang Kontafarma Holdings Ltd <1312.HK>::Parties to share subscription agreement commercially agreed to terminate proposed subscription by co of equity interest in Binex.Unit and Binex entered into an agreement for possible establishment of a joint venture company in prc.Joint venture is proposed to be owned by Huakong Kangtai and Binex as to 51% and 49%, respectively.Establishment of a joint venture company to develop biologics business.  Full Article

Allied Cement issues profit warning<1312.HK>
Friday, 5 Aug 2016 09:12am EDT 

Allied Cement Holdings Ltd <1312.HK>: Profit warning <1312.HK> . The group is expected to record a significant loss for the six months ended 30 June 2016 . Expected result due to decline in the selling prices of cement products in the people's republic of China .  Full Article

Allied Cement Holdings issues FY 2015 profit warning
Wednesday, 17 Feb 2016 05:47am EST 

Allied Cement Holdings Ltd:Expected to record a significant loss for the year ended 31 December 2015.Loss was primarily attributable to a decline in the average selling prices and sales volume of the group's cement products.  Full Article

Allied Cement Holdings Ltd says unit entered into sale and purchase agreement
Thursday, 28 Jan 2016 08:57pm EST 

Allied Cement Holdings Ltd:Discloseable and connected transaction in relation to the acquisition of certain equity interests in a pharmaceutical company in the prc.Unit and the vendor entered into the sale and purchase agreement.Deal for an aggregate consideration of 291.2 million yuan.Says acquisition will be funded by the internal resources of the company.  Full Article

No consensus analysis data available.